Company Filing History:

20 out of 2,405

Merck Sharp + Dohme Corp.

Merck Sharpe & Dohme Corp.

patents

Years Active: 1993-2009

Loading Chart...

28 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7592456 - [object Object] (2009-09-22),

2. 7468393 - Diarylsulfones as 5-HT2A antagonists (2008-12-23),

3. 7452899 - Gamma-secretase inhibitors (2008-11-18),

4. 7217740 - Diarylsulfones as 5-HT2A antagonists (2007-05-15),

5. 7060710 - [object Object] (2006-06-13),

6. 7022724 - Cognition enhancing derivatives of isoxazole triazoloindane GABA-A α5 receptor subunit ligands (2006-04-04),

7. 6949549 - Imidazolophthalazine derivatives as ligands for GABAA receptors (2005-09-27),

8. 6946461 - Imidazolophthalazine derivatives as ligands for GABAA receptors (2005-09-20),

9. 6638930 - Morpholine and thiomorpholine tachykinin receptor antagonists (2003-10-28),

10. 6448249 - Substituted 1,2,4-triazolo[3,4-A]phthalazine derivatives as GABA&agr;5 ligands (2002-09-10),

11. 6444666 - Triazolopyridazine Derivatives for treating anxiety and enhancing cognition (2002-09-03),

12. 6310203 - Precursor compounds to substituted 1,2,4-triazolo[3,4,-a]phathalazine GABA alpha 5 ligands (2001-10-30),

13. 6297235 - Triazolopyridazine derivatives for treating anxiety and enhancing cognition (2001-10-02),

14. 6235735 - Morpholine and thiomorpholine tachykinin receptor antagonists (2001-05-22),

15. 6200975 - Substituted 1,2,4-triazolo[3,4-a]phthalazine derivatives as GABA alpha 5 ligands (2001-03-13),

Title: Innovations in CNS Treatments: The Contributions of Tamara Ladduwahetty

Introduction

Tamara Ladduwahetty, based in London, GB, is a prolific inventor recognized for her significant contributions to the field of medicinal chemistry. With 28 patents to her name, she has developed innovative compounds that have the potential to address various central nervous system (CNS) conditions.

Latest Patents

Among her latest patents, Tamara has worked on compounds of formula (I) that serve as potent and selective 5-HT antagonists. These compounds are useful in treating a variety of adverse conditions related to the CNS. Another notable patent she holds involves diarylsulfones as 5-HT2A antagonists, which also represents potent and selective antagonism of the human 5-HT receptor, further advancing treatments for CNS-related ailments.

Career Highlights

Tamara's impressive career includes tenures at leading pharmaceutical companies like Merck Sharp & Dohme Corporation and Merck & Company, Inc. Her work has significantly impacted the development of new therapeutic drugs focused on mental health and neurological disorders.

Collaborations

Throughout her career, Tamara has collaborated with esteemed colleagues, including Angus Murray MacLeod and Kevin John Merchant. These partnerships have facilitated a rich exchange of ideas, leading to innovative breakthroughs in her research.

Conclusion

Tamara Ladduwahetty's work exemplifies the spirit of innovation in the pharmaceutical industry. Her contributions through various patents are paving the way for more effective treatments for CNS conditions, showcasing the vital role of inventors in enhancing healthcare solutions.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

1 patent (EPO):

Please report any incorrect information to support@idiyas.com